Cancer Clinical Trials

Contact Research Coordinators at (605)322-3228 or email medoncresearch@avera.org for more information.

• We currently have no open studies for this disease site.

Contact Breast Research Coordinators at (605)322-3295 or email breastresearch@avera.org for more information.

• 201209135: A Phase II Study of Neratinib Alone and in Combination with Fulvestrant in Metastatic HER2 Non-amplified but HER2 Mutant Breast Cancer
• Takeda X31025: A Phase 1 Evaluation of the Safety and Tolerability of TAK-128 in Combination with TAK-117 and Paclitaxel in Advanced Solid Tumors
• Tesaro TNE001: A Phase 1 Evaluation of the Safety and Tolerability of Niraparib in Combination with Everolimus in Advanced Ovarian and Breast Cancer
• NSABP B-59/GBG 96-Gepardouze: A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo (Immunotherapy)
• Intraoperative Radiation Therapy (IORT) Registry
• S1418/BR006: A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy (Immunotherapy)
• OSU-16106/Bazan: Multi-Institution Phase II Trial of Intraoperative Electron Beam Radiotherapy Boost at the Time of Breast Conserving Surgery with Oncoplastic Reconstruction in Women with Early-Stage Breast Cancer
• NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer (Immunotherapy)
• NRG-BR005: A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response After Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment Without Surgery
• NSABP FB-14: A Phase II Clinical Trial of Pembrolizumab in Combination with the AE37 Peptide Vaccine in Patients with Metastatic Triple-Negative Breast Cancer (temporarily closed to accrual 17-Sep-2020)

Contact Research Coordinators at (605)322-3086 or (605)322-3295 or (605)322-3018 or (605)322-3295 for more information.

• BCCR: Development and Implementation of the Breast Cancer Collaborative Registry

• NHLBI-MDS: The National Myelodysplastic Syndromes (MDS) Study is for Patients who have persistent unexplained low blood counts, circulating peripheral blasts, or have been recently diagnosed with MDS in the last 6 months and have not received treatment

• A151804: Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

Contact Research Coordinators at (605)322-3221 or (605)322-3291 for more information.

• We currently have no open studies.

Contact Research Coordinators at (605)322-3228 or email medoncresearch@avera.org for more information.

• GI002: A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
• A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair (ATOMIC: Adjuvant Trial of Deficient Mismatch Repair in Colon Cancer) [Immunotherapy]
• NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer - temporarily closed to enrollment 04-Jun-2020
• A021703 - Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
• NRG-GI005: Phase II/III study of Circulating tumOr DNA as a predictive BiomaRker in Adjuvant chemotherapy in stage IIA colon cancer (COBRA)

Contact Research Coordinators at (605)322-3228 or (605)322-3291 for more information.

• Takeda X31025: A Phase 1 Evaluation of the Safety and Tolerability of TAK-128 in Combination with TAK-117 and Paclitaxel in Advanced Solid Tumors
• LOXO-EXT-17005: A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers

Contact Research Coordinators at (605)322-7536 or email gynresearch@avera.org for more information.

• GOG 0263: Stage I/IIA Cervical Cancer
• GOG 0264: Sex Cord-Stromal Tumors of the Ovary
• Takeda X31025: A Phase 1 Evaluation of the Safety and Tolerability of TAK-128 in Combination with TAK-117 and Paclitaxel in Advanced Solid Tumors
• Tesaro TNE001: A Phase 1 Evaluation of the Safety and Tolerability of Niraparib in Combination with Everolimus in Advanced Ovarian and Breast Cancer
• NRG-GY009: A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer(Immunotherapy)
• 3000-03-005/ENGot-OV44: The FIRST: A randomized, Double-Blind, Phase 3 comparison of platinum-based therapy with TSR 042 and niraparib versus standard of care platinum-based therapy as First line treatment of stage III or IV nonmucinous Epithelial ovarian cancer (Immunotherapy)
• NRG-GY016: A Phase II Study of MK-3475 (Pembrolizumab) + Epacadostat in Recurrent Clear Cell Carcinoma of the Ovary (Immunotherapy)
• NRG-GY014: A Phase II Study of Tazemetostat (EPZ-6438)(IND# 138671) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
• NRG-GY018: A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475) in addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
• NRG-GY019: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
• AstraZeneca D6018C004 DUETTE - A Phase 2 Randomised, Multi-Centre Study to Investigate the Efficacy and Tolerability of a Second Maintenance Treatment in Patients with Platinum-Sensitive Relapsed Epithelial Ovarian Cancer, who have Previously Received PARP Inhibitor Maintenance Treatment
• AstraZeneca D9311C00001 / GOG-3041: A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)

Contact Research Coordinators at (605)322-3228 or email medoncresearch@avera.org for more information.

• NRG-HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin
• NRG-HN005: A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
• C-145-03_HNSCC: A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN 145) for the Treatment of Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Contact Research Coordinators at (605)322-3228 or email medoncresearch@avera.org for more information.

• EA2187: A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma

Contact Research Coordinators at (605)322-3086 or (605)322-3291 for more information.

• NSABP B-59/GBG 96-Gepardouze: A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo
• NRG-GY016: A Phase II Study of MK-3475 Pembrolizumab+Epacadostat in Recurrent Clear Cell Carcinoma of the Ovary
• A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair (ATOMIC: Adjuvant Trial of Deficient Mismatch Repair in Colon Cancer)
• 3000-03-005/ENGot-OV44: The FIRST: A randomized, Double-Blind, Phase 3 comparison of platinum-based therapy with TSR 042 and niraparib versus standard of care platinum-based therapy as First line treatment of stage III or IV nonmucinous Epithelial ovarian cancer
• A031501: Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation
• NRG-GY009: A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian - temporarily closed 09-May-2019
• S1418/BR006: A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
• NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
• EA6134: Advanced BRAFV600 Mutant Melanoma

Contact Research Coordinators at (605)322-3090 or email hematologyresearch@avera.org for more information.

• We currently have no open studies for this disease site.

Contact Research Coordinators at (605)322-3228 or email medoncresearch@avera.org for more information.

• Alchemist: Genetic Testing in Screening Patients with Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery - enrollment temporarily suspended 26-Aug-2019
• D9103C00001: A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)
• S1827: MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)

Contact Research Coordinators at (605)322-3090 or email hematologyresearch@avera.org for more information.

• UTX-TGR-205: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma
• JCAR017-FOL-001: A Phase 2, open-label, single-arm, multicohort, multicenter trial to evaluate the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory indolent B-cell non-Hodgkin Lymphoma (NHL) (TRANSCEND FL)

Contact Research Coordinators at (605)322-3228 or email medoncresearch@avera.org for more information.

• EA6134: Advanced BRAFV600 Mutant Melanoma (Immunotherapy)

Contact Research Coordinators at (605)322-3090 or email hematologyresearch@avera.org for more information.

• Takeda C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen
• S1803: Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
• EAA173: Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)

Contact Research Coordinators at (605)322-3090 or email hematologyresearch@avera.org for more information.

• We currently have no open studies for this disease site.

Contact Research Coordinators at (605)322-3090 or email hematologyresearch@avera.org for more information.

• ACE-536-MF-001: A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Luspatercept (ACE-536) in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia with and without Red Blood Cell-Transfusion Dependence
  
• FEDR-MF-001: A Phase 3b, Multicenter, Single-Arm, Open-Label Efficacy and Safety Study of Fedratinib in Subjects with DIPSS-Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia VeraMyelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated with Ruxolitinib (The “FREEDOM” trial)

Contact Research Coordinators at (605)322-3228 or email medoncresearch@avera.org for more information.

• D-US-60010-001 | NAPOLI 3: An open-label, randomized, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas
• QUILT-88: Open-Label, Randomized, Comparative Phase 2 Study of Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for First and Second Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Contact Research Coordinators at (605)322-3228 or email medoncresearch@avera.org for more information.

• We currently have no open studies for this disease site.

Contact Research Coordinators at (605)322-3228 or email medoncresearch@avera.org for more information.

• A031501: Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation (Immunotherapy)

Contact Research Coordinator at (605)322-3016 for more information.

• INCB 18424-MA-GD-301: An Open-label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
• GRAVITAS-309: A Phase 3 Study of Itacitinib or Placebo in Combination with Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease